An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Trial Profile

An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2018

At a glance

  • Drugs SC 006 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 11 May 2018 Planned number of patients changed from 108 to 128.
    • 28 Jun 2017 Planned End Date changed from 19 Feb 2021 to 22 Dec 2020.
    • 30 Mar 2017 Planned End Date changed from 1 Jan 2021 to 1 Feb 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top